Aug. 18 at 5:41 AM
$RFL Investors might be confusing the now exhausted run up to CHMP’s adjudication of the arimoclomol EU application with a negative expectation of TRANSPORT success. Anytime a stock runs 300% higher the wise will lock in profits and the foolish 🙋 hold in hopes of executive share price support. The former happened. The latter did not. Consequently, many buyers are selling at anything north of
$2 which is to be expected quelling any rise into data, at least, for now.
Though not optimistic, I did take heart in the fact that an AI scan determined that parents of Trappsol-Cyclo patients have reported positive experiences in stabilized motor functions; improved swallowing (an exceptional differentiator from arimoclomol) and increased alertness in younger patients (see pic). This bodes well on the primaries.
For biotech OG’s, lots of ex-U.S. trial sites is also auspicious. 😉
The only negative mentioned was hearing loss. Dismissed only by brain loss. See you in another 3-weeks!
